Wugen Nabs $115M for Pivotal Study of Allogeneic CAR-T

Wugen has secured $115 million in a recent funding round to support development of its allogeneic (off-the-shelf) CAR-T cell therapy for T-cell malignancies21.

The company's therapy is notable for being fratricide-resistant, which means it prevents treatment cells from attacking each other, a common problem in T-cell cancer therapies1.

The new funding will be used to run a pivotal clinical trial aimed at supporting an FDA filing expected in 20271.

Wugen's pivotal trial will also support ongoing regulatory discussions with both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)3.

If successful, Wugen's CAR-T therapy could be the first off-the-shelf product for T-cell malignancies to reach the market1.

Sources:

1. https://www.fiercebiotech.com/biotech/wugen-woos-vcs-landing-115m-bring-fratricide-proof-car-t-cell-therapy-market

2. https://www.biopharmadive.com/news/wugen-funding-car-t-allogeneic-off-the-shelf/758726/

3. https://www.clinicaltrialsarena.com/news/wugen-trial-t-cell/